- Home
- CHRS vs MOLN Comparison
CHRS vs MOLN Comparison
Compare CHRS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MOLN
- Stock Information
- Founded
- CHRS 2010
- MOLN 2004
- Country
- CHRS United States
- MOLN Switzerland
- Employees
- CHRS N/A
- MOLN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MOLN
- Sector
- CHRS Health Care
- MOLN
- Exchange
- CHRS Nasdaq
- MOLN Nasdaq
- Market Cap
- CHRS 191.3M
- MOLN 195.4M
- IPO Year
- CHRS 2014
- MOLN 2021
- Fundamental
- Price
- CHRS $1.32
- MOLN $5.30
- Analyst Decision
- CHRS Strong Buy
- MOLN
- Analyst Count
- CHRS 4
- MOLN 0
- Target Price
- CHRS $5.38
- MOLN N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- MOLN 7.1K
- Earning Date
- CHRS 03-12-2025
- MOLN 03-13-2025
- Dividend Yield
- CHRS N/A
- MOLN N/A
- EPS Growth
- CHRS N/A
- MOLN N/A
- EPS
- CHRS N/A
- MOLN N/A
- Revenue
- CHRS $304,340,000.00
- MOLN $7,105,397.00
- Revenue This Year
- CHRS $2.47
- MOLN N/A
- Revenue Next Year
- CHRS N/A
- MOLN $29.41
- P/E Ratio
- CHRS N/A
- MOLN N/A
- Revenue Growth
- CHRS 44.19
- MOLN N/A
- 52 Week Low
- CHRS $0.66
- MOLN $3.32
- 52 Week High
- CHRS $2.87
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- MOLN 48.54
- Support Level
- CHRS $1.38
- MOLN $4.98
- Resistance Level
- CHRS $1.60
- MOLN $5.91
- Average True Range (ATR)
- CHRS 0.12
- MOLN 0.27
- MACD
- CHRS -0.03
- MOLN 0.05
- Stochastic Oscillator
- CHRS 1.10
- MOLN 47.50
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.